Mar 13: Drug manufacturing major Zydus Cadila on Tuesday said that it has received the final approval from the USFDA to market its Tizanidine Tablets USP in the strengths of 2 mg and 4 mg.
According to the company, the drug is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury and works by helping to relax the muscles. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
Based in Ahmedabad, the Pankaj R Patel promoted Zydus Cadila Group is a research driven drug maker that discovers, develops, manufactures and markets a broad range of healthcare therapies.
The group now has more than 180 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Cadila Healthcare, the group’s listed entity, were trading at Rs 394.20, up 1.23% from the previous closing of Rs 389.40, on BSE at 11.08 pm today.